Physician profile
Samden D Lhatoo
NPI 1831411693
$65,546.08
in general payments reported to CMS, 2019-2025
22 companies · $7,842 in 2025
The $7,842 reported for 2025 was more than what 87% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,085 · 2020: $3,594 · 2021: $1,038 · 2022: $8,275 · 2023: $1,699 · 2024: $41K · 2025: $7,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $15K · Consulting Fee: $12K · Food and Beverage: $4,849 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,631.00 |
| Travel and Lodging | $15,112.42 |
| Consulting Fee | $11,945.00 |
| Food and Beverage | $4,849.22 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $34,024.70 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy, Vns Therapy Symmetry Model 8103 Generator |
| Ucb, INC. | $9,403.56 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Medtronic, INC. | $6,132.17 | 2022-2023 | Activa PC |
| Ucb Sa | $3,850.00 | 2024 | Fintepla |
| Greenwich Biosciences, INC. | $3,528.96 | 2019-2021 | |
| Neuropace, INC. | $3,393.00 | 2020-2025 | |
| Sk Life Science, INC. | $2,714.53 | 2020-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $1,395.52 | 2022-2025 | Epidiolex |
| Eisai INC. | $222.07 | 2019-2022 | |
| Neurelis, INC. | $154.19 | 2025 | Valtoco |
| Sumitomo Pharma America, INC. | $141.26 | 2023 | Aptiom |
| Ceribell, INC. | $119.42 | 2024 | Pocket Eeg Device |
| Aucta Pharmaceuticals, INC. | $102.54 | 2025 | Motpoly Xr |
| Otter Pharmaceuticals, LLC | $97.34 | 2024-2025 | Sympazan |
| Sunovion Pharmaceuticals INC. | $63.56 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.62 | 2025 | Infinity |
| Catalyst Pharmaceuticals, INC. | $33.61 | 2023-2024 | Fycompa |
| Csl Behring | $32.99 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $24.25 | 2023 | Daybue |
| Abbvie INC. | $23.67 | 2024 | |
| Zogenix INC. | $23.13 | 2021 | |
| Amneal Pharmaceuticals LLC | $21.99 | 2024 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samden Lhatoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.